Envisia Therapeutics Announces Company President, Dr. Ben Yerxa, Will Present at the 35th J.P. Morgan Healthcare Conference

RESEARCH TRIANGLE PARK, N.C., Jan. 4, 2017 /PRNewswire/ -- Envisia Therapeutics today announced that Company President, Dr. Benjamin Yerxa, has been invited to present at the 35^th Annual J.P. Morgan Healthcare Conference taking place January 9 -13^th, 2017 in San Francisco, CA. The J.P. Morgan Healthcare Conference continues to be one of the life science industry's largest conferences of the year, bringing thousands of investors and executives from around the world to exchange the latest innovations in the industry. Details are as follows:

Event:  35th Annual J.P. Morgan Healthcare Conference
Date:   Tuesday, January 10, 2017
Time:   4:30 pm PST / 7:30 pm EST

ENV515 is a fully biodegradable, PRINT®-particle formulation of a marketed prostaglandin analog that has the potential to lower intraocular pressure (IOP) for more than six months from a single extended-release dosage form. ENV515 was designed to address the issue of poor patient compliance that exists today with daily eye drops to limit the progression of glaucoma that sometimes leads to vision loss or blindness. Envisia is also leveraging the PRINT-platform to develop products for other leading ocular diseases, including age-related macular degeneration (AMD) and diabetic macular edema (DME).

ABOUT ENVISIA THERAPEUTICS™
Envisia Therapeutics is a privately held biotechnology company focused on the development of novel ocular therapies. Envisia is leveraging the unique and powerful properties of the PRINT® technology to develop therapies for a variety of ocular conditions, beginning with ENV515 for glaucoma. ENV515 is a novel, extended-release formulation of a marketed prostaglandin analogue that has the potential to significantly limit disease progression and vision loss through improved product performance and patient compliance. Envisia is actively exploring the use of the Company's unique technology to develop products for other important ocular diseases including age-related macular degeneration (AMD), diabetic macular edema (DME), and ocular inflammation. Envisia is located in Research Triangle Park, North Carolina. For more information, please go to www.envisiatherapeutics.com.

SOURCE Envisia Therapeutics